To include your compound in the COVID-19 Resource Center, submit it here.

NeuroCell-PD: Phase II

GENZ and partner DCRN said preliminary analysis of a U.S. Phase II trial in 18 patients with severe PD showed NeuroCell-PD did not meet its

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE